<DOC>
	<DOCNO>NCT00097851</DOCNO>
	<brief_summary>PI-88 new experimental drug inhibits tumour growth reduce formation new blood vessel tumours . Docetaxel standard second-line treatment offer patient non-small-cell lung cancer n't respond first-line therapy ( platinum-based drug radiotherapy ) . Of group patient , 20 % remain progression-free 6 month start docetaxel treatment . The PR88202 study design compare two different cancer treatment ( docetaxel , docetaxel plus PI-88 ) work effective cancer . It hop combination PI-88 docetaxel allow patient extend time take disease progress , also improve quality life .</brief_summary>
	<brief_title>Trial PI-88 With Docetaxel Advanced Non-Small-Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>PR88202 open-label randomize study . In initial phase study , patient randomize receive weekly docetaxel alone , PI-88 combination weekly docetaxel . Both group receive docetaxel ( 30 mg/m2 ) , administer intravenous infusion day 1 , 8 15 28-day cycle . The second group receive PI-88 ( 250 mg/day ) addition docetaxel ; PI-88 administer subcutaneous injection day 1-4 , 8-11 15-18 cycle . The primary efficacy endpoint non-progression rate 6 month . In extension phase study , patient combination arm stable disease objective response six treatment cycle remain PI-88 alone maintenance therapy . Patients initially receive docetaxel alone disease progression unacceptable toxicity completion six cycle eligible receive PI-88 alone third-line therapy .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>histologically cytologically confirm stage IIIb IV NSCLC progress firstline treatment measurable disease spiral CT chest scan , defined RECIST criterion performance status 01 ( ECOG ) life expectancy least 2 month adequate hemopoietic , renal hepatic function current symptomatic central nervous system ( CNS ) involvement prior coexistent malignancy significant nonmalignant disease acute chronic gastrointestinal ( GI ) bleed last two year inflammatory bowel disease abnormal bleeding tendency patient risk bleed due open wound plan surgery clinically significant hemoptysis within past 4 week bilirubin &gt; upper limit normal ( ULN ) ALT AST &gt; 2.5 time ULN , &gt; 1.5 time ULN alkaline phosphatase &gt; 2.5 time ULN alkaline phosphatase &gt; 5 time ULN , unless patient bone metastases myocardial infarction , stroke congestive heart failure within last 3 month prior treatment docetaxel concomitant treatment aspirin ( &gt; 100 mg/day ) , NSAIDs ( except selective COX2 inhibitor , warfarin ( &gt; 1 mg/day ) , heparin , LMWH , antiplatelet drug , CYP3A4 inhibitor woman pregnant breastfeed woman childbearing potential use adequate contraception history allergy and/or hypersensitivity anticoagulant thrombolytic agent , especially heparin history immunemediated thrombocytopenia , thrombotic thrombocytopenic purpura platelet disease allergy polysorbate 80 ( component TaxotereÂ® ) uncontrolled serious infection last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>second-line</keyword>
	<keyword>combination</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>anti-angiogenic</keyword>
</DOC>